 In contrast, cohort 3 is a randomized, double-blind, placebo-controlled, cross-over design, multiple dose study to assess the efficacy, safety, tolerability and pharmacokinetics of inhaled QBW276 over 4 weeks in patients with cystic fibrosis who are homozygous for the F508del mutation. 